AR059738A1 - Analogos de meridamicina para el tratamiento de trastornos neurodegenerativos - Google Patents
Analogos de meridamicina para el tratamiento de trastornos neurodegenerativosInfo
- Publication number
- AR059738A1 AR059738A1 ARP070100899A ARP070100899A AR059738A1 AR 059738 A1 AR059738 A1 AR 059738A1 AR P070100899 A ARP070100899 A AR P070100899A AR P070100899 A ARP070100899 A AR P070100899A AR 059738 A1 AR059738 A1 AR 059738A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- alkyl
- aryl
- heterocyclyl
- meridamicine
- Prior art date
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- 125000000623 heterocyclic group Chemical group 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000003107 substituted aryl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Reivindicacion 1: Un compuesto de la estructura (1): en donde: R1 y R2 están independientemente seleccionados del grupo que consiste en, OH, oxo, O(alquilo C1-6), O(alquilo C1-6 sustituido), O(acilo), O(arilo), O(arilo sustituido), u O(heterociclilo), O(heterociclilo sustituido); R3, R4, R5, y R6 están independientemente seleccionados del grupo que consiste en OH, oxo, O(alquilo C1-6), O(alquilo C1-6 sustituido), O(acilo), O(arilo), O(arilo sustituido) O(heterociclilo), y O(heterociclilo sustituido); o R3 y R4 y/o R5 y R6 se unen conjuntamente para formar una estructura (2): o R4 y R5 se unen para formar una estructura (3): en donde X e Y están independientemente seleccionados del grupo que consiste en H, alquilo C1- 6, alquilo C1-6 sustituido, arilo, arilo sustituido, heterociclilo, y heterociclilo sustituido; R7 es CH2, CHOH, o C=O; y n es 1 o 2; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77994006P | 2006-03-07 | 2006-03-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR059738A1 true AR059738A1 (es) | 2008-04-23 |
Family
ID=38289934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070100899A AR059738A1 (es) | 2006-03-07 | 2007-03-05 | Analogos de meridamicina para el tratamiento de trastornos neurodegenerativos |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7745457B2 (es) |
| EP (1) | EP1991551A1 (es) |
| JP (1) | JP2009529049A (es) |
| KR (1) | KR20080099317A (es) |
| CN (1) | CN101426796A (es) |
| AR (1) | AR059738A1 (es) |
| AU (1) | AU2007223962A1 (es) |
| BR (1) | BRPI0708611A2 (es) |
| CA (1) | CA2643350A1 (es) |
| CR (1) | CR10272A (es) |
| EC (1) | ECSP088718A (es) |
| IL (1) | IL193414A0 (es) |
| MX (1) | MX2008011312A (es) |
| NO (1) | NO20083695L (es) |
| PE (1) | PE20081550A1 (es) |
| RU (1) | RU2008132779A (es) |
| TW (1) | TW200804400A (es) |
| WO (1) | WO2007103347A1 (es) |
| ZA (1) | ZA200807678B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HN2005035605A (es) * | 2004-12-20 | 2010-08-05 | Wyeth Corp | Analogos de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos, proliferativos e inflamatorios |
| BRPI0519593A2 (pt) * | 2004-12-20 | 2009-02-25 | Wyeth Corp | composto, mÉtodos de tratar distérbios neurodegenerativos e complicaÇÕes devido a derrame ou trauma na cabeÇa, e de preparar um composto, e, uso de um composto |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9302016D0 (en) | 1993-02-02 | 1993-03-17 | Sandoz Ltd | Compounds |
| GB9318144D0 (en) | 1993-09-01 | 1993-10-20 | Sandoz Ltd | Organic compounds |
| WO1995014023A1 (en) | 1993-11-19 | 1995-05-26 | Abbott Laboratories | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
| US7247650B2 (en) * | 2004-03-02 | 2007-07-24 | Wyeth | Macrolides and methods for producing same |
| CN1929837A (zh) * | 2004-03-02 | 2007-03-14 | 惠氏公司 | 作为神经保护剂和/或神经再生剂的非免疫抑制的亲免素配体 |
| JP2008501342A (ja) * | 2004-06-03 | 2008-01-24 | ワイス | 複合ポリケチドを生成するための生合成遺伝子クラスター |
| WO2006053313A2 (en) * | 2004-11-12 | 2006-05-18 | Wyeth | Elaiophylin biosynthetic gene cluster |
| HN2005035605A (es) | 2004-12-20 | 2010-08-05 | Wyeth Corp | Analogos de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos, proliferativos e inflamatorios |
| BRPI0519593A2 (pt) | 2004-12-20 | 2009-02-25 | Wyeth Corp | composto, mÉtodos de tratar distérbios neurodegenerativos e complicaÇÕes devido a derrame ou trauma na cabeÇa, e de preparar um composto, e, uso de um composto |
-
2007
- 2007-03-05 CA CA002643350A patent/CA2643350A1/en not_active Abandoned
- 2007-03-05 RU RU2008132779/04A patent/RU2008132779A/ru not_active Application Discontinuation
- 2007-03-05 AR ARP070100899A patent/AR059738A1/es unknown
- 2007-03-05 CN CNA2007800078343A patent/CN101426796A/zh active Pending
- 2007-03-05 MX MX2008011312A patent/MX2008011312A/es not_active Application Discontinuation
- 2007-03-05 US US11/713,972 patent/US7745457B2/en not_active Expired - Fee Related
- 2007-03-05 WO PCT/US2007/005645 patent/WO2007103347A1/en not_active Ceased
- 2007-03-05 BR BRPI0708611-3A patent/BRPI0708611A2/pt not_active Application Discontinuation
- 2007-03-05 EP EP07752355A patent/EP1991551A1/en not_active Withdrawn
- 2007-03-05 JP JP2008558346A patent/JP2009529049A/ja active Pending
- 2007-03-05 TW TW096107510A patent/TW200804400A/zh unknown
- 2007-03-05 KR KR1020087021820A patent/KR20080099317A/ko not_active Withdrawn
- 2007-03-05 AU AU2007223962A patent/AU2007223962A1/en not_active Abandoned
- 2007-03-09 PE PE2007000263A patent/PE20081550A1/es not_active Application Discontinuation
-
2008
- 2008-08-12 IL IL193414A patent/IL193414A0/en unknown
- 2008-08-27 NO NO20083695A patent/NO20083695L/no not_active Application Discontinuation
- 2008-09-05 EC EC2008008718A patent/ECSP088718A/es unknown
- 2008-09-05 CR CR10272A patent/CR10272A/es not_active Application Discontinuation
- 2008-09-05 ZA ZA200807678A patent/ZA200807678B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101426796A (zh) | 2009-05-06 |
| BRPI0708611A2 (pt) | 2011-06-07 |
| US7745457B2 (en) | 2010-06-29 |
| RU2008132779A (ru) | 2010-04-20 |
| PE20081550A1 (es) | 2008-12-31 |
| NO20083695L (no) | 2008-10-03 |
| US20070213525A1 (en) | 2007-09-13 |
| AU2007223962A1 (en) | 2007-09-13 |
| JP2009529049A (ja) | 2009-08-13 |
| EP1991551A1 (en) | 2008-11-19 |
| ECSP088718A (es) | 2008-10-31 |
| CR10272A (es) | 2008-10-03 |
| CA2643350A1 (en) | 2007-09-13 |
| MX2008011312A (es) | 2008-09-12 |
| KR20080099317A (ko) | 2008-11-12 |
| ZA200807678B (en) | 2009-08-26 |
| IL193414A0 (en) | 2009-05-04 |
| TW200804400A (en) | 2008-01-16 |
| WO2007103347A1 (en) | 2007-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022001739A1 (es) | Compuestos tricíclicos sustituidos | |
| ES2634490T3 (es) | Derivados de ácido napht-2-ylacetico para tratar el sida | |
| CL2011003302A1 (es) | Compuestos derivados de amida del acido alquil-sulfonico; composicion farmaceutica; uso de los compuestos como moduladores de la disfuncion de glutamato para prevenir o tratar trastornos neurologicos y psiquiatricos como esquizofrenia, enfermedad de alzheimer, trastornos de deficit de atencion/hiperactividad, perdida de audicion, entre otros. | |
| AR068510A1 (es) | Derivados de 4-fenil-1h-piridin-2-ona - 1,3 disustituidos, composiciones farmaceuticas que los contienen y usos de los mismos para tratar o prevenir trastornos del sistema nervioso central. | |
| PE20151651A1 (es) | Derivado de tetrahidroimidazol[1,5-d][1,4]oxazepina | |
| PE20251288A1 (es) | Compuestos heterociclicos como inmunomoduladores | |
| MX377359B (es) | Compuestos mono y espirocíclicos que continen ciclobutano y azetidina como inhibidores de la integrina alfa v. | |
| AR065622A1 (es) | Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona | |
| CR9721A (es) | Compuestos de carbamato para utilizar en el tratamiento de desordenes neurodegenerativos | |
| NI201200012A (es) | Profármacos que comprenden un conjugado de insulina - conector | |
| UY30411A1 (es) | Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones | |
| UY30414A1 (es) | Metano sulfonatos, propano-1-sulfonatos y ciclopropan sulfonatos sustituidos con [2,3,4,8-tetrahidroimidazo-[1,5-al-pirimidin-8-il]-fenilo, composiciones farmacéuticas conteniéndolos y aplicaciones. | |
| EA201391158A1 (ru) | Диаминиевые соли фенотиазина и их применение | |
| AR112532A2 (es) | Compuestos de tetraciclina sustituidos con flúor en c7 | |
| EA201791802A1 (ru) | СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС | |
| EA200900178A1 (ru) | Конденсированные гетероциклические производные и их применение | |
| AR068051A1 (es) | Compuestos moduladores de la pi3k quinasa,composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del cancer. | |
| AR101177A1 (es) | Inhibidores de la syk | |
| AR091858A1 (es) | INHIBIDORES DE CISTATIONIN-g-LIASA (CSE) | |
| DOP2006000170A (es) | Nuevos derivados de espirocromanona | |
| AR065815A1 (es) | Compuestos de dihidroindazol en el tratamiento de trastornos del hierro | |
| AR077080A1 (es) | Compuestos de 2,3-dihidro-1h-indeno | |
| AR070885A1 (es) | Compuestos de azaindol para el tratamiento de trastornos del sistema nervioso central | |
| MA38079A1 (fr) | Composés de 2-phényl-5-hétérocyclyl-tétrahydro-2h-pyran-3-amine destinés à être utilisés dans le traitement du diabète et de ses troubles associés | |
| CR20150419A (es) | Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |